Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme-Reference-Cited by-同舟云学术

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme

Published:2018-06-14 Issue:9 Volume:73 Page:2519-2523
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Stone Gregory G¹,Newell Paul²,Gasink Leanne B³,Broadhurst Helen²,Wardman Angela²,Yates Katrina²,Chen Zhangjing⁴,Song Jie⁴,Chow Joseph W³^ORCID

Affiliation:

1. AstraZeneca Pharmaceuticals, 35 Gatehouse Drive, Waltham, MA 02451, USA

2. AstraZeneca Global Medicines Development, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK

3. AstraZeneca, 1800 Concord Pike, Wilmington, DE 19803, USA

4. AstraZeneca, 199 Liangjing Road, Shanghai 201203, China

Funder

RECLAIM 1 and 2

RECLAIM 3

REPRISE

RECAPTURE 1 and 2

REPROVE

AstraZeneca

Pfizer

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/73/9/2519/25523303/dky204.pdf

Reference20 articles.

1. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management;Barbier;Curr Opin Pulm Med,2013

2. The challenge of antimicrobial resistance in managing intra-abdominal infections;Sartelli;Surg Infect (Larchmt),2015

3. The emerging threat of multidrug-resistant Gram-negative bacteria in urology;Zowawi;Nat Rev Urol,2015

4. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe;Cantón;Clin Microbiol Infect,2012

5. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value;Flamm;J Chemother,2014

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance in Pseudomonas aeruginosa: A Narrative Review of Antibiogram Interpretation and Emerging Treatments;Antibiotics;2023-11-12

2. Management strategies for severe Pseudomonas aeruginosa infections;Current Opinion in Infectious Diseases;2023-10-12

3. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme;Journal of Antimicrobial Chemotherapy;2023-09-13

4. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study;Antimicrobial Agents and Chemotherapy;2023-08-17

5. Severe infections caused by difficult-to-treat Gram-negative bacteria;Current Opinion in Critical Care;2023-07-31